TRIANA Biomedicines Announces Publication of Preclinical Data Supporting Clinical Advancement of TRI-611
TRIANA Biomedicines, Inc. (TRIANA), a clinical-stage biopharmaceutical company focused on developing innovative molecular glue therapies for difficult-to-drug disease targets, leveraging its target-first and proximity-first molecular glue discovery platform, today announced the publication of a manuscript titled “TRI-611, a selective, brain-penetrant molecular glue degrader of ALK,” in the international peer-reviewed scientific journal, Nature. These preclinical results support the ongoing clinical development of TRI-611, which will be featured in a Trial-in-Progress poster presentation at European Society of Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain.
TRIANA Biomedicines Announces the Appointment of Mohan Bala as Chief Operating Officer and Attracts Leading Experts to its Scientific Advisory Board
TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease targets, today announced the appointment of Dr. Mohan Bala as Chief Operating Officer (COO). Additionally, Drs. Maria Koehler and David Tuveson join the Company’s growing Scientific Advisory Board (SAB).
TRIANA Biomedicines Announces Oral Presentation of TRI-611 and Additional Poster Presentations at the American Association for Cancer Research Annual Meeting 2026
TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease targets, today announced one oral and three poster presentations regarding the Company’s clinical asset, TRI-611, as well as its preclinical asset Cyclin E1 (CCNE1) will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22, 2026 in San Diego, California.
TRIANA Biomedicines’ TRI-611 Granted U.S. FDA Fast Track Designation for Treatment of ALK Positive Non-small Cell Lung Cancer
TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease targets, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for TRI-611, an investigational molecular glue degrader therapy for the treatment of anaplastic lymphoma kinase–positive (ALK+) non-small cell lung cancer (NSCLC).
TRIANA Biomedicines Announces First Patient Dosed in a Phase 1/2 Trial Evaluating TRI-611 for the Treatment of ALK Positive Non-small Cell Lung Cancer
TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease targets, today announced that the first patient has been dosed in a Phase 1/2 clinical trial evaluating TRI-611, a novel ALK-fusion molecular glue degrader, in patients with anaplastic lymphoma kinase–positive (ALK+) non-small cell lung cancer (NSCLC).
TRIANA Biomedicines Announces Oversubscribed $120M Series B Financing to Advance its Molecular Glue Degrader Pipeline
TRIANA Biomedicines, Inc. (TRIANA), a leading biopharmaceutical company focused on advancing a target-first and proximity-first molecular glue discovery platform to address difficult to drug disease targets, today announced the successful closing of its oversubscribed $120 million Series B financing round.
TRIANA Biomedicines Launches With $110M to Unlock the Full Potential of Molecular Glues
TRIANA Biomedicines, Inc. (Triana) today announced their launch with $110 million in total funding to establish a best-in-class, scalable platform to discover and develop “molecular glues”. Triana’s platform aims to generate products that stabilize pre-existing or create de novo interactions between two proteins and alter the fate or functionality of the disease target. Molecular glues may allow for the pursuit of highly disease-relevant targets long considered undruggable or inadequately addressed by traditional drug discovery approaches.
